ASCO GU 2023 Bladder Cancer

Viewing 1-20 of 54 articles

ASCO GU 2023: Sequencing Systemic Therapies and Looking to the Horizon for Metastatic Urothelial Carcinoma

ASCO GU 2023: Radiation Therapy in Oligometastatic and Local Recurrence Urothelial Carcinoma: The What, Why, and How

ASCO GU 2023: Biomarkers of Response to Enfortumab Vedotin in Patients with Advanced Urothelial Carcinoma: Analysis of the UNITE Study

ASCO GU 2023: Optimizing Survival for Patients With Muscle-Invasive Bladder Cancer

ASCO GU 2023: Next-Generation Therapies in Nonmuscle-Invasive Bladder Cancer

ASCO GU 2023: Prediction of Response to Neoadjuvant Chemotherapy of Patients with Muscle Invasive Bladder Cancer by Molecular Subtyping and Radioligand Target Quantitation: Preview of the Bladder BRIDGister

ASCO GU 2023: Impact of Race and Payer Status on the Choice of Urinary Diversion Among Patients with Localized Bladder Carcinoma Undergoing Cystectomy

ASCO GU 2023: 54: 68Ga-PSMA-11 Patients with Newly Diagnosed and Recurrent Prostate Cancer (FIREFLY Study): Preliminary Results

ASCO GU 2023: Patient-Reported Outcomes in Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin Alone or in Combination with Pembrolizumab in the Phase 1b/2 EV-103 Cohort K

ASCO GU 2023: Sequential Intravesical Gemcitabine and Docetaxel Versus Bacillus Calmette-Guérin for the Treatment of High-Risk, Treatment-Naïve, Non-Muscle Invasive Bladder Cancer

ASCO GU 2023: Extended Follow-Up Results CheckMate 274 Trial and Results of Pembrolizumab Monotherapy in BCG-Unresponsive HR NMIBC: Findings from Cohort B of the KEYNOTE-057 Trial

ASCO GU 2023: EV-104: Phase 1 Study of Intravesical Enfortumab Vedotin for Treatment of Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)

ASCO GU 2023: IMvigor130 and the Future of Immune Checkpoint Inhibitors in the First-Line Treatment of Metastatic Urothelial Carcinoma

ASCO GU 2023: Pembrolizumab Monotherapy for Patients with High-Risk Non–muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette–Guérin (BCG): Results from Cohort B of the Phase 2 KEYNOTE-057 Trial

ASCO GU 2023: Addressing Health Equity by Expanding Trial Eligibility Criteria in Urothelial Carcinoma

ASCO GU 2023: Extended Follow-up Results from the CheckMate 274 Trial

ASCO GU 2023: The Impact of the Financial Cost: How Much Is It Costing Our Patients With Bladder Cancer?

ASCO GU 2023: Gender Specific Differences in Health-Related Quality of Life for Patients with Bladder Cancer Following Radical Cystectomy

ASCO GU 2023: Atezolizumab + Platinum/gemcitabine vs Placebo + Platinum/Gemcitabine for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: Final OS from the Randomized Phase 3 IMvigor130 Study

ASCO GU 2023: Final OS Analysis of Atezolizumab Monotherapy vs Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial Carcinoma from the Phase 3 IMvigor130 Study

1
2
3